Hjem › Kronisk lymfatisk leukæmi › Illinois › Chicago
Kronisk lymfatisk leukæmi kliniske forsøg i Chicago, IL
14 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i og omkring Chicago (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RekruttererFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- og 1 flere
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekruttererFase 3
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekruttererFase 3
- Northwestern University, Chicago
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RekruttererFase 3
- Northwestern University, Chicago
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruttererFase 3
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RekruttererFase 1
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruttererFase 1
- University of Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RekruttererFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- The University of Chicago Medical Center, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruttererFase 4
- Northwestern University, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruttererFase 4
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekruttererFase 1
- Northwestern Memorial Hospital, Chicago
Kronisk lymfatisk leukæmi forsøg i andre byer
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN19 studier
- New York City, NY18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Cincinnati, OH14 studier
- Nashville, TN13 studier
Andre studier i Chicago
- Ikke-småcellet lungecancer61 studier
- Brystkræft58 studier
- Kræft (alle typer)51 studier
- Metastatisk cancer45 studier
- Prostatakræft45 studier
- Overvægt41 studier
- Lungecancer41 studier
- Ægstockræft36 studier
- Slagtilfælde34 studier
- Colorektal kræft33 studier
- Hjertesvigt31 studier
- Overvægt28 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.